US OptionsDetailed Quotes
BRBR241220C72500
- 5.70
- -1.10-16.18%
15min DelayClose Nov 27 16:00 ET
6.30High5.70Low
6.30Open6.80Pre Close4 Volume114 Open Interest72.50Strike Price2.46KTurnover35.95%IV1.35%PremiumDec 20, 2024Expiry Date4.66Intrinsic Value100Multiplier21DDays to Expiry1.04Extrinsic Value100Contract SizeAmericanOptions Type0.7851Delta0.0436Gamma13.54Leverage Ratio-0.0527Theta0.0321Rho10.63Eff Leverage0.0545Vega
BellRing Brands Stock Discussion
Sign in to post a comment
Hey everyone! Like I mentioned in the last post, the big news is that MoomooCA has set up a server for me, and it's open for all of you to join! It’s called Trader’s Tavern, and yes—the profile pic is my cat <3
In there, I’ll be sharing more in-depth stock analysis, including entry and target points, plus detailed descriptions of each stock. It’d be great if you all could join us there!
In the meantime, here’s our mid-month update on some stocks I’m keeping an eye on! Let’s aim f...
In there, I’ll be sharing more in-depth stock analysis, including entry and target points, plus detailed descriptions of each stock. It’d be great if you all could join us there!
In the meantime, here’s our mid-month update on some stocks I’m keeping an eye on! Let’s aim f...
10
2
Insider selling at BellRing Brands, particularly when share price was low, is discouraging. The absence of insider buying in the past year and recent selling activity calls for caution. Despite profit growth, the history of sales warrants careful consideration before purchasing stock.
1
The CEO, Darcy Davenport, expressed increased confidence in the full year due to a strong start to 2024, which led to the decision to raise the company's outlook.
BellRing Brands and Olaplex outperformed expectations last quarter, while Nu Skin and Estée Lauder fell short. Overall, the personal care sector remains resilient with shares up 16.9%.
CEO Darcy Davenport reports strong momentum across BellRing Brands (BRBR), attributing profitable winds to the convenient nutrition category, and foresees bright future for the company.
Gainers:
In reaction to earnings/guidance:
• $GoodRx (GDRX.US)$ +38.5%, $EDGIO (EGIO.US)$ +13.5%, $Lemonade (LMND.US)$ +10.7%, $Desktop Metal (DM.US)$ +8.5%, $ShockWave Medical (SWAV.US)$ +8.2%, $Pubmatic (PUBM.US)$ +8.1%, $Olaplex (OLPX.US)$ +7%, $Vivid Seats (SEAT.US)$ +6.4%, $Noble (NE.US)$ +6.3%, $Aspen Technology (AZPN.US)$ +5.4%, $AAON Inc (AAON.US)$ +5%, $Hudbay Minerals (HBM.US)$ +5%, $Vivint Smart Home (VVNT.US)$ +4.9%, $Vivint Smart Home (VVNT.US)$ +4...
In reaction to earnings/guidance:
• $GoodRx (GDRX.US)$ +38.5%, $EDGIO (EGIO.US)$ +13.5%, $Lemonade (LMND.US)$ +10.7%, $Desktop Metal (DM.US)$ +8.5%, $ShockWave Medical (SWAV.US)$ +8.2%, $Pubmatic (PUBM.US)$ +8.1%, $Olaplex (OLPX.US)$ +7%, $Vivid Seats (SEAT.US)$ +6.4%, $Noble (NE.US)$ +6.3%, $Aspen Technology (AZPN.US)$ +5.4%, $AAON Inc (AAON.US)$ +5%, $Hudbay Minerals (HBM.US)$ +5%, $Vivint Smart Home (VVNT.US)$ +4.9%, $Vivint Smart Home (VVNT.US)$ +4...
24
Gainers:
• $SpringWorks Therapeutics (SWTX.US)$ +19.2% (Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase3DeFi Trial )
• $Roivant Sciences (ROIV.US)$ +7.1% (FDA has approved VTAMA (tapinarof) cream)
• $Ocugen (OCGN.US)$ +5.9% (announces that it is diversifying its innovative pipeline by introducing a Phase 3 cell therapy platform technology called Ne?Cart)
• $Champion Homes (SKY.US)$ +4.4% (In reaction to earnings）
• $NetEase (NTES.US)$ +4.1% (In...
• $SpringWorks Therapeutics (SWTX.US)$ +19.2% (Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase3DeFi Trial )
• $Roivant Sciences (ROIV.US)$ +7.1% (FDA has approved VTAMA (tapinarof) cream)
• $Ocugen (OCGN.US)$ +5.9% (announces that it is diversifying its innovative pipeline by introducing a Phase 3 cell therapy platform technology called Ne?Cart)
• $Champion Homes (SKY.US)$ +4.4% (In reaction to earnings）
• $NetEase (NTES.US)$ +4.1% (In...
11
According to the disclosure of the US Securities and Exchange Commission (SEC), $Blackrock (BLK.US)$ , the world's largest asset management company, submitted a position report (13F) for the first quarter (Q1) ended March 31, 2022.
From the perspective of position preference
BlackRock favors technology stocks, accounting for 24.78% of the total position. It was followed by financials and healthcare stocks, which acco...
From the perspective of position preference
BlackRock favors technology stocks, accounting for 24.78% of the total position. It was followed by financials and healthcare stocks, which acco...
8
No comment yet
Smangler : Send a link to the tavern I want to join
SpeedyStud OP Smangler : Join the server Trader’s Tavern with us
Here is the link🫶